Shares of Stevanato Group SpA (STVN, Financial) fell 6.63% in mid-day trading on Sep 30. The stock reached an intraday low of $19.89, before recovering slightly to $19.92, down from its previous close of $21.33. This places STVN 44.00% below its 52-week high of $35.56 and 20.26% above its 52-week low of $16.56. Trading volume was 462,548 shares, 103.3% of the average daily volume of 447,670.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Stevanato Group SpA (STVN, Financial) is $26.86 with a high estimate of $37.12 and a low estimate of $21.07. The average target implies an upside of 34.89% from the current price of $19.92. More detailed estimate data can be found on the Stevanato Group SpA (STVN) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Stevanato Group SpA's (STVN, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Stevanato Group SpA (STVN, Financial) in one year is $28.88, suggesting a upside of 45.02% from the current price of $19.915. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Stevanato Group SpA (STVN) Summary page.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
